Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex. Its earlier-stage clinical pipeline also includes INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug for rare pulmonary disorders. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INSM
CUSIPN/A
Phone908-977-9900
Debt
Debt-to-Equity Ratio0.83
Current Ratio14.14
Quick Ratio14.14
Price-To-Earnings
Trailing P/E Ratio-7.74
Forward P/E Ratio-5.54
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.71 per share
Price / Book4.77
Profitability
EPS (Most Recent Fiscal Year)($2.89)
Net Income$-192,640,000.00
Net MarginsN/A
Return on Equity-63.81%
Return on Assets-41.10%
Miscellaneous
Employees214
Outstanding Shares77,040,000
Market Cap$1.64 billion
Insmed (NASDAQ:INSM) Frequently Asked Questions
What is Insmed's stock symbol?
Insmed trades on the NASDAQ under the ticker symbol "INSM."
How were Insmed's earnings last quarter?
Insmed Incorporated (NASDAQ:INSM) issued its quarterly earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.08) by $0.09. View Insmed's Earnings History.
When is Insmed's next earnings date?
What price target have analysts set for INSM?
7 analysts have issued 12 month price targets for Insmed's shares. Their forecasts range from $25.00 to $54.00. On average, they expect Insmed's stock price to reach $39.00 in the next year. This suggests a possible upside of 73.4% from the stock's current price. View Analyst Price Targets for Insmed.
What is the consensus analysts' recommendation for Insmed?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insmed.
Who are some of Insmed's key competitors?
Some companies that are related to Insmed include Alkermes (ALKS), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Ligand Pharmaceuticals (LGND), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), GW Pharmaceuticals PLC- (GWPH), Agios Pharmaceuticals (AGIO), Ultragenyx Pharmaceutical (RARE), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Endo International (ENDP) and Intercept Pharmaceuticals (ICPT).
Who are Insmed's key executives?
Insmed's management team includes the folowing people:
- Mr. William H. Lewis, Pres, CEO & Director (Age 49)
- Ms. Christine A. Pellizzari, Chief Legal Officer (Age 50)
- Mr. Roger Adsett, Chief Commercial Officer (Age 49)
- Dr. Paul Streck, Chief Medical Officer (Age 55)
- Mr. Paolo Tombesi, Chief Financial Officer (Age 54)
Who are Insmed's major shareholders?
Insmed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Redmile Group LLC (2.64%), Voya Investment Management LLC (1.37%), Northern Trust Corp (1.28%), Emerald Advisers Inc. PA (0.94%), Nexthera Capital LP (0.84%) and Bellevue Group AG (0.55%). Company insiders that own Insmed stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden Jr, Melvin Md Sharoky, Myrtle S Potter and Orlov S Nicole Schaeffer. View Institutional Ownership Trends for Insmed.
Which major investors are selling Insmed stock?
INSM stock was sold by a variety of institutional investors in the last quarter, including Nexthera Capital LP, Redmile Group LLC, Alps Advisors Inc., WINTON GROUP Ltd, California Public Employees Retirement System and Emerald Advisers Inc. PA. Company insiders that have sold Insmed company stock in the last year include Donald J Hayden Jr and Orlov S Nicole Schaeffer. View Insider Buying and Selling for Insmed.
Which major investors are buying Insmed stock?
INSM stock was bought by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, American Century Companies Inc., Bellevue Group AG, Macquarie Group Ltd., C WorldWide Group Holding A S, Asymmetry Capital Management L.P., Chartwell Investment Partners LLC and Northern Trust Corp. View Insider Buying and Selling for Insmed.
How do I buy shares of Insmed?
Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insmed's stock price today?
One share of INSM stock can currently be purchased for approximately $22.49.
How big of a company is Insmed?
Insmed has a market capitalization of $1.64 billion. The biopharmaceutical company earns $-192,640,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Insmed employs 214 workers across the globe.
What is Insmed's official website?
How can I contact Insmed?
Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]
MarketBeat Community Rating for Insmed (NASDAQ INSM)
MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe INSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
